Targeted Oncology

Exploring the transformative potential of FDA-approved CAR T-cell therapies cilta-cel and ide-cel for relapsed/refractory multiple myeloma. Marc Braunstein, MD, PhD, shares insights from 90+ oncologists on their application in early relapse. Sign up now to access the full article: https://hubs.li/Q03cnLyh0 #NYU #oncology #cancernews #CancerAwareness #myeloma #mmsm #multiplemyeloma #exclusive NYU Langone Health

The presence of mKRAS ctDNA in plasma and peritoneal fluid was associated with increased risk of metastatic progression and worse overall survival in patients with localized pancreatic ductal adenocarcinoma. #PDAC #pancsm https://hubs.li/Q03dmMkr0

The #FDA approved cabozantinib for adult and pediatric patients aged 12+ with previously treated, unresectable, locally advanced/metastatic, well-differentiated pancreatic neuroendocrine tumors & well-differentiated extra-pancreatic neuroendocrine tumors. https://hubs.li/Q03dsT2T0

The #FDA granted fast track designation to azercabtagene zapreleucel for the treatment of patients with relapsed/refractory #DLBCL. https://hubs.li/Q03db1dm0

Increased testing to identify patients with HRD-negative or BRCA1/2+ tumors could expand access to targeted treatments such as PARP inhibitors for those with epithelial ovarian cancer or metastatic breast cancer. #bcsm #gyncsm https://hubs.li/Q03dkDzr0

March is #NutritionAwarenessMonth—a timely reminder of nutrition’s evolving role in oncology. From prevention to survivorship, diet impacts cancer outcomes, but emerging evidence demands we rethink traditional paradigms. ?? Key Considerations: ? Prevention: How do specific dietary patterns (e.g., Mediterranean, plant-based) modulate risk? ? Treatment: Can targeted nutrition mitigate toxicity or enhance efficacy? ? Survivorship: What interventions reduce recurrence risk or comorbidity burden? New data challenges old assumptions—let’s discuss the gaps and opportunities. How are you integrating nutrition into your practice? #Oncology #CancerNutrition Learn more in this special report featuring insights from Marleen I. Meyers, MD, a breast medical oncologist at NYU Langone Health: https://hubs.li/Q03d6vbL0

By 2037, US oncologist demand (26,620) will outpace supply (24,630), with a 15% vs. 7% increase, highlighting a growing workforce shortage. https://hubs.li/Q03cYRwk0

A new AI-powered software, Unfold AI, has demonstrated its ability to estimate tumor volume, which is strongly linked to biopsy outcomes following focal cryoablation, according to a study conducted by researchers at UCLA Health and published in BJUI Compass. https://hubs.li/Q03d4QTD0

The #FDA has cleared the IND application for EVM14, an off-the-shelf TAA vaccine, for the potential treatment of various cancers, including #NSCLC and head and neck cancer. https://hubs.li/Q03d8RLr0

In this week's Targeted Pulse, we cover positive data and developments to be aware of in #AML, breast cancer, #PDAC, and #NMIBC. #bcsm